Eton Pharmaceuticals, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Eton Pharmaceuticals, Inc. (ETON) reported Adjustments to Additional Paid in Capital, Warrant Issued of $1.17 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-03-19
- Eton Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-12-31 was $0.00.
- Eton Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-09-30 was $1.17M.
- Eton Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2022-09-30 was $0.00.
- Eton Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2022-06-30 was $244.00K.
- Eton Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $1.17M.
- Eton Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2018 was $3.10M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.17M derived: sum of 2 quarters · filed 2026-03-19 | $1.17M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $1.17M 10-Q · filed 2025-11-06 | $1.17M 10-Q · filed 2025-11-06 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $244.00K derived: sum of 2 quarters · filed 2023-11-09 | $244.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $244.00K 10-Q · filed 2023-08-10 | $244.00K 10-Q · filed 2023-08-10 | ||
| 2018-12-31 | $3.10M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |